Appendix II — H — Decisions Cited — H
Ninth Edition, Revision 01.2024
[ Editor Note: Opinions of the Patent Trial and Appeal Board or its predecessor organizations (Board) made available to the public after the Board first published Standard Operating Procedure 2 in 1994 (addressing the publication of Board opinions and the designation of such opinions as precedential) that (1) expressly indicate that the opinion is binding precedent of the Board or (2) are identified as binding precedent on the Board’s Precedential opinion website ( www.uspto.gov/patents-application-process/appealing -patent-decisions/decisions-and-opinions/precedential ) are precedential and binding authority. Prior to 1994, a decision by the Board was considered binding on panels of the Board only if the opinion was authorized by the Board to be published. See Ex parte Holt, 19 USPQ2d 1211 (Bd.Pat. App. & Int. 1991).]
Editor Note: When possible, parallel citations to the United States Reports or Federal Reporter and the United States Patent Quarterly (USPQ) are provided and include pinpoint pages, if appropriate. However, decisions of the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit published after July 11, 2022, no longer contain a pinpoint page for the USPQ citations.
Hack, In re, 245 F.2d 246, 114 USPQ 161 (CCPA 1957) 2112.02
Hadco Products, Inc., v. Lighting Corp. of America, Inc., 312 F. Supp 1173, 165 USPQ 496 (E.D. Pa. 1970) 1503.02
Hafner, In re, 410 F.2d 1403, 161 USPQ 783 (CCPA 1969) 211.05
Hageman, Ex parte, 179 USPQ 747 (Bd. App. 1971) 211.05
Hahn v. Wong, 892 F.2d 1028, 13 USPQ2d 1313 (Fed. Cir. 1989) 2305
Hale, Ex parte, 49 USPQ 209 (Bd. App. 1941) 715.09 , 717.01(f)
Hall, Ex parte, 83 USPQ 38 (Bd. App. 1949) 2173.05(d) , 2175
Hall, In re, 208 F.2d 370, 100 USPQ 46 (CCPA 1953) 2173.05(j)
Hall, In re, 781 F.2d 897, 228 USPQ 453 (Fed. Cir. 1986) 2128 , 2128.01 , 2128.02 , 2152.02(e)
Hall v. Macneale, 107 U.S. 90 (1882) 2133.03(a)
Halleck, In re, 422 F.2d 911, 164 USPQ 647 (CCPA 1970) 2173.05(c)
Haller, Ex parte, 103 USPQ 332 (Bd. App. 1953) 2127
Halliburton Energy Servs., Inc. v. M-I LLC, 514 F.3d 1244, 85 USPQ2d 1654 (Fed. Cir. 2008) 2173.02 , 2173.05(g)
Hallmark Cards, Inc. v. Lehman, 959 F. Supp. 539, 42 USPQ2d 1134 (D.D.C. 1997) 1480
Hamilton, In re, 882 F.2d 1576, 11 USPQ2d 1890 (Fed. Cir. 1989) 2133.03(c) , 2133.03(e)(7)
Hammack, In re, 427 F.2d 1378, 166 USPQ 204 (CCPA 1970) 2173.03
Hammack, In re, 427 F.2d 1384, 166 USPQ 209 (CCPA 1970) 2173.05(e)
Hanback, Ex parte, 231 USPQ 739 (Bd. Pat. App. & Inter. 1986) 1504.04
Hardee, In re, 223 USPQ 1122 (Comm’r Pat. 1984) 2109
Hargraves, In re, 53 F.2d 900, 11 USPQ 240 (CCPA 1931) 804
Harley v. Lehman, 981 F. Supp. 9, 44 USPQ2d 1699 (D.D.C. 1997) 1308
Harnisch, In re, 631 F.2d 716, 206 USPQ 300 (CCPA 1980) 803.02 , 2117
Harrington Mfg. Co. v. Powell Mfg. Co., 815 F.2d 1478, 2 USPQ2d 1364 (Fed. Cir. 1986) 2133.03(e)(2)
Harris, In re, 409 F.3d 1339, 74 USPQ2d 1951 (Fed. Cir. 2005) 2144.05
Harry, In re, 333 F.2d 920, 142 USPQ 164 (CCPA 1964) 715.07 , 2138.06
Hartop, In re, 311 F.2d 249, 135 USPQ 419 (CCPA 1962) 2107.01 , 2107.03
Haruna, In re, 249 F.3d 1327, 58 USPQ2d 1517 (Fed. Cir. 2001) 1504.03
Harvey, In re, 12 F.3d 1061, 29 USPQ2d 1206 (Fed. Cir. 1993) 1504.03 , 1504.04
Harwood, In re, 390 F.2d 985, 156 USPQ 673 (CCPA 1968) 2107.01
Harza, In re, 274 F.2d 669, 124 USPQ 378 (CCPA 1960) 2144.04
Hasche, Ex parte, 86 USPQ 481 (Bd. App. 1949) 2173.05(d) , 2175
Haskell v. Colebourne, 671 F.2d 1362, 213 USPQ 192 (CCPA 1982) 2138.06
Hata, Ex parte, 6 USPQ2d 1652 (Bd Pat. App. & Int. 1987) 2404.02
Hawkins, In re, 486 F.2d 569, 179 USPQ 157 (CCPA 1973) 608.01(p)
Hawkins, In re, 486 F.2d 579, 179 USPQ 163 (CCPA 1973) 608.01(p)
Hawkins, In re, 486 F.2d 577, 179 USPQ 167 (CCPA 1973) 608.01(p)
Hayes, In re, 53 USPQ2d 1222 (Comm’r Pat. 1999) 1412.03 , 1414.03
Hay, In re, 534 F.2d 917, 189 USPQ 790 (CCPA 1976) 608.01(h) , 2165.01 , 2407.02
Hays v. Sony Corp. of Am., 847 F.2d 412, 7 USPQ2d 1043 (7th. Cir. 1988) 410
Hazeltine Research Inc. v. Brenner, 382 U.S. 252, 147 USPQ 429 (1965) 2136.02 , 2158
Heany, In re, 1911 C.D. 138 (Comm’r Pat. 1911) 2012 , 2012.01
Hearing Components, Inc. v. Shure Inc., 600 F.3d 1357, 94 USPQ2d 1385 (Fed. Cir. 2010) 2145 , 2173.05(b)
Heck, In re, 699 F.2d 1331, 216 USPQ 1038 (Fed. Cir. 1983) 804 , 2123
Heckman, Ex parte, 135 USPQ 229 (P.O. Super. Exam. 1960) 1504.05
Hedges, In re, 783 F.2d 1038, 228 USPQ 685 (Fed. Cir. 1986) 1207.03(a) , 2145
Hedgewick v. Akers, 497 F.2d 905, 182 USPQ 167 (CCPA 1974) 2137
Heinl v. Godici, 143 F. Supp. 2d 593 (E.D. Va. 2001) 2246 , 2258.01 , 2274
Hellbaum, In re, 371 F.2d 1022, 152 USPQ 571 (CCPA 1967) 2190
Hellsund, In re, 474 F.2d 1307, 177 USPQ 170 (CCPA 1973) 715
Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S.Ct. 628, 129 USPQ2d 1189 (2019) 2133.03 , 2133.03(b) , 2152.02(d)
Hengehold, In re, 440 F.2d 1395, 169 USPQ 473 (CCPA 1971) 821 , 1201 , 2274 , 2731
Henrich, Ex parte, 1913 Dec. Comm’r Pat. 139 (Comm’r Pat. 1913) 711.03(c)
Henriksen, In re, 399 F.2d 253, 158 USPQ 224 (CCPA 1968) 211.01(b)
Heritage, In re, 182 F.2d 639, 86 USPQ 160 (CCPA 1950) 901.02
Herman v. Huddleston, 459 U.S. 375 (1983) 2107.02
Herman v. William Brooks Shoe Co., 39 USPQ2d 1773 (S.D.N.Y. 1996) 410
Herr, In re, 377 F.2d 610, 153 USPQ 548 (CCPA 1967) 2190
Herrmann, In re, 261 F.2d 598, 120 USPQ 182 (CCPA 1949) 707.07(f)
Hershberger, Ex parte, 96 USPQ 54 (Bd. App. 1952) 2128.01
Herschler, In re, 591 F.2d 693, 200 USPQ 711 (CCPA 1979) 2161.01 , 2163 , 2163.05
Herz, In re, 537 F.2d 549, 190 USPQ 461 (CCPA 1976) 2111.03
Hester Industries, Inc. v. Stein, Inc., 142 F.3d 1472, 46 USPQ2d 1641 (Fed. Cir. 1998) 1412.01 , 1412.02
Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 15 USPQ2d 1525 (Fed. Cir. 1990) 2114
Hiatt v. Ziegler, 179 USPQ 757 (Bd. Pat. Inter. 1973) 2138.04
Hibberd, Ex parte, 227 USPQ 443 (Bd. Pat. App. & Inter. 1985) 1601
Hidy, In re, 303 F.2d 954, 133 USPQ 650 (CCPA 1962) 715.05 , 804.02
High Concrete Structures Inc. v. New Enter. Stone & Lime Co., 377 F.3d 1379, 71 USPQ2d 1948 (Fed. Cir. 2004) 2165.04
Hildebrand, Ex parte, 15 USPQ2d 1662 (Bd. Pat. App. & Inter. 1990) 2404.01 , 2410.01
Hill, In re, 284 F.2d 955, 128 USPQ 197 (CCPA 1960) 716.02(d)
Hill-Rom Co. v. Kinetic Concepts, Inc., 209 F.3d 1337, 54 USPQ2d 1437 (Fed. Cir. 2000) 1302.04 , 2181
Hilmer, In re, 359 F.2d 859, 149 USPQ 480 (CCPA 1966) 715 , 2136 , 2136.03 , 2154.01(b)
Hilton, Ex parte, 148 USPQ 356 (Bd. App. 1965) 2144.04
Hiniker Co., In re, 150 F.3d 1362, 47 USPQ2d 1523 (Fed. Cir. 1998) 2103 , 2242 , 2258 , 2258.01 , 2274 , 2816.02
Hirao, In re, 535 F.2d 67, 190 USPQ 15 (CCPA 1976) 2141.02
Hirschfield v. Banner, 462 F. Supp 135, 200 USPQ 276 (D.D.C. 1978) 2164.06(c)
Hirschler, Ex parte, 110 USPQ 384 (Bd. App. 1952) 2132.01
Hitchings, In re, 342 F.2d 80, 144 USPQ 637 (CCPA 1965) 2164.01(c)
Hitzeman v. Rutter, 243 F.3d 1345, 58 USPQ2d 1161 (Fed. Cir. 2001) 2138.04
Hiyamizu, Ex parte, 10 USPQ2d 1393 (Bd. Pat. App. & Inter. 1988) 2141.03
Hobbs v. United States, 451 F.2d 849, 171 USPQ 713 (5th Cir. 1971) 2133.03 , 2133.03(b)
Hoch, In re, 428 F.2d 1341, 166 USPQ 406 (CCPA 1970) 1207.03 , 2142 , 2144.08
Hockerson-Halberstadt, Inc. v. Avia Group Int’l, 222 F.3d 951, 55 USPQ2d 1487 (Fed. Cir. 2000) 2125
Hodosh v. Block Drug Co., Inc., 786 F.2d 1136, 229 USPQ 182 (Fed. Cir. 1986) 2144.08
Hoechst Aktiengesellschaft v. Quigg, 917 F.2d 522, 16 USPQ2d 1549 (Fed. Cir. 1990) 2758
Hoechst-Roussel Pharmaceuticals Inc. v. Lehman, 109 F.3d 756, 42 USPQ2d 1220 (Fed. Cir. 1997) 2158 , 2751
Hoeksema, In re, 399 F.2d 269, 158 USPQ 596 (CCPA 1968) 2121.01 , 2121.02 , 2141.01 , 2144.09 , 2145
Hoeschele, In re, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) 2144.05
Hoffer v. Microsoft Corp., 405 F.3d 1326, 74 USPQ2d 1481 (Fed. Cir. 2005) 2111.04
Hoffman, Ex parte, 12 USPQ2d 1061 (Bd. Pat. App. & Inter. 1989) 2111.03
Hoffman v. Klaus, 9 USPQ2d 1657 (Bd. Pat. App. & Inter. 1988) 2107.02
Hoffman-La Roche, Inc. v. Promega Corp., 323 F.3d 1354, 66 USPQ2d 1385 (Fed. Cir. 2003) 608.01(p) , 2004
Hogan, In re, 559 F.2d 595, 194 USPQ 527 (CCPA 1977) 2124 , 2164.05(a)
Holladay, In re, 584 F.2d 384, 199 USPQ 516 (CCPA 1978) 716.02(e)
Hollingsworth, In re, 253 F.2d 238, 117 USPQ 182 (CCPA 1958) 716.03(a)
Holmwood v. Cherpeck, 2 USPQ2d 1942 (Bd. Pat. App. & Inter. 1986) 2138.03
Honeywell v. Diamond, 499 F. Supp. 924, 208 USPQ 452 (D.D.C. 1980) 2165.04
Honigsbaum v. Lehman, 903 F. Supp 8, 37 USPQ2d 1799 (D.D.C. 1995) 513
Honn, In re, 364 F.2d 454, 150 USPQ 652 (CCPA 1966) 608.01(h) , 2165.01
Hook, Ex parte, 102 USPQ 130 (Bd. App. 1953) 715.07
Hormone Research Foundation Inc. v. Genentech Inc., 904 F.2d 1558, 15 USPQ2d 1039 (Fed. Cir. 1990) 2173.05(a)
Horton, Ex parte, 226 USPQ 697 (Bd. Pat. App. & Inter. 1985) 2258
Hospira, Inc. v. Fresenius Kabi USA, LLC, 946 F.3d 1322, 2020 USPQ2d 6227 (Fed. Cir. 2020) 2112
Hostettler, In re, 356 F.2d 562, 148 USPQ 514 (CCPA 1966) 715.03
Hough, In re, 108 USPQ 89, 703 O.G.200 (Comm’r Pat. 1955) 409.03(i)
Houghton, In re, 433 F.2d 820, 167 USPQ 687 (CCPA 1970) 2107.01
Hovlid v. Asari, 305 F.2d 747, 134 USPQ 162 (9th Cir. 1962) 201.06(d) , 211.01(b)
Howarth, In re, 654 F.2d 103, 210 USPQ 689 (CCPA 1981) 716.09 , 2164.01(b)
Hozumi, Ex parte, 3 USPQ2d 1059 (Bd. Pat. App. & Inter. 1984) 2117
Hruby, In re, 373 F.2d 997, 153 USPQ 61 (CCPA 1967) 1504.01(a)
Huang, In re, 100 F.3d 135, 40 USPQ2d 1685 (Fed. Cir. 1996) 716.01(b) , 716.03 , 716.03(b) , 1504.01(c)
Hubbell, In re, 709 F.3d 1140, 106 USPQ2d 1032 (Fed. Cir. 2013) 804
Huber, Ex parte, 148 USPQ 447 (Bd. Pat. App. & Inter. 1965) 2172.01
Huelster v. Reiter, 168 F.2d 542, 78 USPQ 82 (CCPA 1948) 2138.06
Hughes, In re, 345 F.2d 184, 145 USPQ 467 (CCPA 1965) 1207.03(a)
Hull v. Bonis, 214 USPQ 731 (Bd. Pat. Inter. 1982) 2138.05
Hull v. Davenport, 90 F.2d 103, 33 USPQ 506 (CCPA 1937) 2138.01 , 2138.06
Humber, Ex parte, 217 USPQ 265 (Bd. App. 1961) 716.02(e)
Humphreys, Ex parte, 24 USPQ2d 1255 (Bd. Pat. App. & Inter. 1992) 2404.01 , 2405
Hunt Co. v. Mallinckrodt Chem. Works, 177 F.2d 583, 83 USPQ 277 (2d Cir. 1949) 211.05 , 1504.20
Hupp v. Siroflex of America, Inc., 122 F.3d 1456, 43 USPQ2d 1887 (Fed. Cir. 1997) 1504.02
Huston v. Ladner, 973 F.2d 1564, 23 USPQ2d 1910 (Fed. Cir. 1992) 2305
Hyatt, In re, 211 F.3d 1367, 54 USPQ2d 1664 (Fed. Cir. 2000) 2111
Hyatt, In re, 708 F.2d 712, 218 USPQ 195 (Fed. Cir. 1983) 2164.08(a) , 2173.05(g) , 2181
Hyatt v. Boone, 146 F.3d 1348, 47 USPQ2d 1128 (Fed. Cir. 1998) 2138.05 , 2163 , 2163.03 , 2304.02(c)
Hyatt v. Dudas, 492 F.3d 1365, 83 USPQ2d 1373 (Fed. Cir. 2007) 2163 , 2163.04
Hyatt v. Dudas, 551 F.3d 1307, 89 USPQ2d 1465 (Fed. Cir. 2008) 1204 , 2163 , 2163.04
Hyatt v. Hirshfeld, 998 F.3d 1347, 2021 USPQ2d 591 (Fed. Cir. 2021) 2190
Hyatt v. USPTO, 797 F.3d 1374, 116 USPQ2d 1331 (Fed. Cir. 2015) 2005
Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 231 USPQ 81 (Fed. Cir. 1986) 716.03(b) , 2138.04 , 2145 , 2163 , 2164.01 , 2164.05(a) , 2184
Hycor Corp. v. The Schlueter Co., 740 F.2d 1529, 222 USPQ 553 (Fed. Cir. 1984) 2004
Hynix Semiconductor Inc. v. Rambus Inc., 645 F.3d 1336, 98 USPQ2d 1711 (Fed. Cir. 2011) 2161.01
Cited authority
- 2112.02 Process Claims
- 1503.02 Drawing
- 211.05 Sufficiency of Disclosure in Prior-Filed Application
- 2305 Requiring a Priority Showing
- 715.09 Timely Presentation
- 717.01(f) Seasonable (or Timely) Presentation
- 2173.05(d) Exemplary Claim Language (“for example,” “such as”)
- 2175 Form Paragraphs for Use in Rejections Under 35 U.S.C. 112(b) or Pre-AIA 35 U.S.C. 112, Second Paragraph
- 2173.05(j) Old Combination
- 2128 “Printed Publications” as Prior Art
- 2128.01 Level of Public Accessibility Required
- 2128.02 Date Publication Is Available as a Reference
- 2152.02(e) Otherwise Available to the Public
- 2133.03(a) “Public Use”
- 2173.05(c) Numerical Ranges and Amounts Limitations
- 2127 Domestic and Foreign Patent Applications as Prior Art
- 2173.02 Determining Whether Claim Language is Definite
- 2173.05(g) Functional Limitations
- 1480 Certificates of Correction — Office Mistake
- 2133.03(c) The “Invention”
- 2133.03(e)(7) Activity of an Independent Third Party Inventor
- 2173.03 Correspondence Between Specification and Claims
- 2173.05(e) Lack of Antecedent Basis
- 1504.04 Considerations Under 35 U.S.C. 112
- 2109 Inventorship
- 804 Definition of Double Patenting
- 1308 Withdrawal From Issue
- 803.02 Election of Species Requirements – Markush Claims
- 2117 Markush Claims
- 2133.03(e)(2) Intent
- 2144.05 Obviousness of Similar and Overlapping Ranges, Amounts, and Proportions
- 715.07 Facts and Documentary Evidence
- 2138.06 “Reasonable Diligence”
- 2107.01 General Principles Governing Utility Rejections
- 2107.03 Special Considerations for Asserted Therapeutic or Pharmacological Utilities
- 1504.03 Nonobviousness
- 2144.04 Legal Precedent as Source of Supporting Rationale
- 2404.02 Biological Material That Can Be Made or Isolated Without Undue Experimentation
- 608.01(p) Completeness of Specification
- 1412.03 Broadening Reissue Claims
- 1414.03 Supplemental Reissue Oath/Declaration
- 608.01(h) Mode of Operation of Invention
- 2165.01 Considerations Relevant to Best Mode
- 2407.02 After a Patent Has Issued
- 410 Representations to the U.S. Patent and Trademark Office
- 2136.02 Content of the Prior Art Available Against the Claims
- 2158 AIA 35 U.S.C. 103
- 2012 Reissue Applications Involving Issues of Fraud, Inequitable Conduct, and/or Violation of Duty of Disclosure
- 2012.01 Collateral Estoppel
- 2145 Consideration of Applicant’s Rebuttal Arguments and Evidence
- 2173.05(b) Relative Terminology
- 2123 Rejection Over Prior Art’s Broad Disclosure Instead of Preferred Embodiments
- 1504.05 Restriction
- 1207.03(a) Determining Whether a Ground of Rejection is New
- 2137 Pre-AIA 35 U.S.C. 102(f)
- 2246 Decision Ordering Reexamination under 35 U.S.C. 304
- 2258.01 Use of Previously Cited/Considered Art in Rejections
- 2274 Appeal Brief
- 2190 Prosecution Laches and Res Judicata
- 715 Swearing Behind a Reference — Affidavit or Declaration Under 37 CFR 1.131(a)
- 2133.03 Rejections Based on “Public Use” or “On Sale”
- 2133.03(b) “On Sale”
- 2152.02(d) On Sale
- 821 Treatment of Claims Held To Be Drawn to Nonelected Inventions
- 1201 Introduction
- 2731 Period of Adjustment
- 711.03(c) Petitions Relating to Abandonment
- 211.01(b) Claiming the Benefit of a Nonprovisional Application
- 901.02 Abandoned Applications
- 2107.02 Procedural Considerations Related to Rejections for Lack of Utility
- 707.07(f) Answer All Material Traversed
- 2161.01 Computer Programming, Computer Implemented Inventions, and 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, First Paragraph
- 2163 Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112(a) or Pre-AIA 35 U.S.C. 112, first paragraph, “Written Description” Requirement
- 2163.05 Changes to the Scope of Claims
- 2111.03 Transitional Phrases
- 1412.01 Reissue Claims Must Be for Same General Invention
- 1412.02 Recapture of Canceled Subject Matter
- 2114 Apparatus and Article Claims — Functional Language
- 2138.04 “Conception”
- 1601 Introduction: The Act, Scope, Type of Plants Covered
- 715.05 U.S. Patent or Application Publication Claiming Same Invention
- 804.02 Avoiding a Double Patenting Rejection
- 2165.04 Examples of Evidence of Concealment
- 2404.01 Biological Material That Is Known and Readily Available to the Public
- 2410.01 Conditions of Deposit
- 716.02(d) Unexpected Results Commensurate in Scope With Claimed Invention
- 1302.04 Examiner’s Amendments and Changes
- 2181 Identifying and Interpreting a 35 U.S.C. 112(f) or Pre-AIA 35 U.S.C. 112, Sixth Paragraph Limitation
- 2136 Pre-AIA 35 U.S.C. 102(e)
- 2136.03 Critical Reference Date
- 2154.01(b) Determining When Subject Matter Was Effectively Filed Under AIA 35 U.S.C. 102(d)
- 2103 Patent Examination Process
- 2242 Criteria for Deciding Request Filed under 35 U.S.C. 302
- 2258 Scope of Ex Parte Reexamination
- 2816.02 Criteria for Making the Determination
- 2141.02 Differences Between Prior Art and Claimed Invention
- 2164.06(c) Examples of Enablement Issues – Computer Programming Cases
- 2132.01 Overcoming a Pre-AIA 35 U.S.C. 102(a) Rejection based on a Printed Publication or Patent
- 2164.01(c) How to Use the Claimed Invention
- 2141.03 Level of Ordinary Skill in the Art
- 1207.03 New Ground of Rejection in Examiner’s Answer
- 2142 Legal Concept of Prima Facie Obviousness
- 2144.08 Obviousness of Species When Prior Art Teaches Genus
- 2125 Drawings as Prior Art
- 2758 Notice of Final Determination - Calculation of Patent Term Extension
- 2751 Eligibility Requirements
- 2121.01 Use of Prior Art in Rejections Where Operability is in Question
- 2121.02 Compounds and Compositions — What Constitutes Enabling Prior Art
- 2141.01 Scope and Content of the Prior Art
- 2144.09 Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers)
- 2111.04 “Adapted to,” “Adapted for,” “Wherein,” “Whereby,” and Contingent Clauses
- 2004 Aids to Compliance With Duty of Disclosure
- 2124 Exception to the Rule That the Reference Must be Prior Art
- 2164.05(a) Specification Must Be Enabling as of the Filing Date
- 716.02(e) Comparison With Closest Prior Art
- 716.03(a) Commercial Success Commensurate in Scope With Claimed Invention
- 2138.03 “By Another Who Has Not Abandoned, Suppressed, or Concealed It”
- 513 Deposit as Priority Mail Express® with U.S. Postal Service
- 2173.05(a) New Terminology
- 2112 Requirements of Rejection Based on Inherency; Burden of Proof
- 715.03 Genus-Species, Practice Relative to Cases Where Predictability Is in Question
- 409.03(i) Rights of the Nonsigning Inventor
- 201.06(d) 37 CFR 1.53(d) Continued Prosecution Application (CPA) Practice
- 716.09 Sufficiency of Disclosure
- 2164.01(b) How to Make the Claimed Invention
- Title Page Title Page
- 716.01(b) Nexus Requirement and Evidence of Nonobviousness
- 716.03 Commercial Success
- 716.03(b) Commercial Success Derived From Claimed Invention
- 1504.01(c) Lack of Ornamentality
- 2172.01 Unclaimed Essential Subject Matter
- 2138.05 “Reduction to Practice”
- 2138.01 Interference Practice
- 2405 Acceptable Depository
- 1504.20 Benefit Under 35 U.S.C. 120
- 1504.02 Novelty
- 2111 Claim Interpretation; Broadest Reasonable Interpretation
- 2164.08(a) Single Means Claim
- 2163.03 Typical Circumstances Where Adequate Written Description Issue Arises
- 2304.02(c) Explaining Priority
- 2163.04 Burden on the Examiner with Regard to the Written Description Requirement
- 1204 Notice of Appeal
- 2005 Comparison to Requirements for Information
- 2164.01 Test of Enablement
- 2184 Determining Whether an Applicant Has Met the Burden of Proving Nonequivalence After a Prima Facie Case Is Made